Interest of Functional MRI (Magnetic Resonance Imagery) (in Patients Suffering From Hepatocellular Carcinoma and Treated With Yttrium (ICY)

Inclusion Criteria:

• Early, intermediate, advanced, non metastatic Hepatocellular Carcinoma. Indication for radioembolization validated after pluridisciplinary committee meeting.
• Isolated target on initial imagery (invasive hepatocellular carcinoma excluded)
• WHO (World Health organization) Performance status: 0, 1 or 2
• If cirrhosis, Child A score with total bilirubin less than 30 micromoles per liter
• Creatinine clearance more or equal to 30 mL/min
• Patient informed and consent signature obtained

Exclusion Criteria:

• Invasive hepatocellular carcinoma without any isolated tumor
• Disease needing 2 injections of Therasphere
• Thrombosis extending into the porta(thrombosis of one of left or right branch authorized), extra hepatic metastasis
• Previous treatment by chemoembolization, radiofrequency less than 3 months before radioembolization
• No antiangiogenic concomitant treatment, 15 days before and 15 days after radioembolization, including Sorafenib
• Associated disease which could prevent patient from receiving treatment
• RMI contre-indication(particle or metal prosthesis, pacemaker, claustrophobia) or contrast product contre-indication (allergy)
• Patient already participating in an other therapeutic trial with an experimental drug
• Pregnant or childbearing potential women or breastfeeding women
• minors, persons deprived of liberty or protected adults (maintenance of justice, guardianship or supervision) Unable to comply with trial medical follow-up for geographical, social or psychological reasons
• Unable to sign an informed consent